Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Condition: Primary Mediastinal (Thymic) Large B-Cell Lymphoma Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Drug: Etoposide Phosphate; Biological: Filgrastim; Biological: Nivolumab; Biological: Pegfilgrastim; Drug: Prednisolone; Drug: Prednisone; Radiation: Radiation Therapy; Biological: Rituximab; Biol ogical: Rituximab and Hyaluronidase Human; Drug: Vincristine Sulfate Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Filgrastim | Immunotherapy | Lymphoma | Neulasta | Neupogen | Prednisolone | Prednisone | Research | Rituxan